Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57407—Specifically defined cancers
  • G01N33/57423—Specifically defined cancers of lung
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
  • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
  • G01N2333/4701—Details
  • G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Definitions

• the present invention relates to a method aiding in the assessment of pulmonary or lung cancer (LC) and in particular in the assessment of non-small cell lung carcinoma (NSCLC). It discloses the use of the “calcyclin-binding protein” (CYBP) as a marker of LC, particularly of NSCLC. Furthermore, it especially relates to a method for assessing lung cancer from a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection of lung cancer or in the surveillance of patients who undergo surgery.
• CYBP calcyclin-binding protein
• LC LC is a frequent cancer in the Western world and among the most frequent causes of cancer-related mortality. This is in large part due to the diagnostic gap for early detection of the disease. LC is largely asymptomatic in its early stages. The majority of all lung cancers is detected at a late stage when the disease has already become inoperable.
• SCLC small cell lung carcinoma
• NSCLC non-small cell lung carcinoma
• CA squamous cell carcinoma
• adeno CA comprising the subclasses of acinar CA, papillary CA, bronchoalveolar tumor, solid tumor, and mixed subtypes
• large cell carcinoma comprising the subclasses of giant cell tumors, clear cell CA, adenosquamous CA, and undifferentiated CA.
• NSCLC if detected at late stages, also has a very poor prognosis.
• the staging of cancer is the classification of the disease in terms of extent, progression, cell type and tumor grade. It groups cancer patients so that generalizations can be made about prognosis and the choice of therapy.
• TNM the most widely used classification system based on the anatomical extent of cancer. It represents an internationally accepted, uniform staging system. There are three basic variables: T (the extent of the primary tumor), N (the status of regional lymph nodes) and M (the presence or absence of distant metastases).
• TNM criteria are published by the UICC (International Union against Cancer), edition, 1997 (Sobin, L. H., and Fleming, I. D., TNM 80 (1997) 1803-4).
• Surgical resection of the primary tumor is widely accepted as the treatment of choice for early stage NSCLC.
• stage Ma T3N1M0, T1N2M0, T2N2M0, T3N2M0
• Mb T4N0M0, T4N1M0, T4N2M0
• a significant shift in the physician's approach is precipitated.
• the cancer is detected during the more early stages (Ia-IIIa; preferably up to stage T3N1M0)
• the five-year survival rate varies between 35% and 80%.
• Detection at stage Ia ((T1N0M0); small tumor size, no metastasis) has evidently the best prognosis with a five-year survival of up to 80%.
• Stage IV corresponds to distant metastasis, i.e., spread of the disease beyond the lungs and regional lymph nodes.
• the five-year survival rate in the later stages III and IV drops to between less than 15% and 1%, respectively.
• early assessment of LC refers to an assessment at a tumor stage of between Ia and Ma, as defined above.
• LC is assessed at a stage of between Ia and IIIa.
• cytoceratin 19 The soluble 30 kDa fragment of cytoceratin 19 (CYFRA 21-1), carcinoembryogenic antigen (CEA), neuron-specific enolase (NSE), and squamous cell carcinoma antigen (SCC) are the most prominent LC markers. However, none of them meets the criteria for sensitivity and specificity required for a screening tool (Thomas, L., Labor and Diagnose (2000) TH Books Verlagsgesellschaft, Frankfurt/Main, Germany).
• a new diagnostic marker as a single marker should be comparable to other markers known in the art, or better. Or, a new marker should lead to a progress in diagnostic sensitivity and/or specificity either if used alone or in combination with one or more other markers, respectively.
• the diagnostic sensitivity and/or specificity of a test is best assessed by its receiver-operating characteristics, which will be described in detail below.
• CYFRA 21-1 is currently regarded to be the best of the presently known tumor markers for lung cancer. Even though not organ-specific, it is predominantly found in lung tissue. Sensitivity of CYFRA 21-1 for lung cancer is described to be between 46-61% at a specificity of 95% towards other benign lung diseases. Increased serum levels of CYFRA 21-1 are also associated with pronounced benign liver diseases, renal insufficiency and invasive bladder cancer. CYFRA 21-1 testing is recommended for postoperative therapy surveillance.
• CEA belongs to the group of carcinofetal antigens, usually produced during embryogenesis. CEA is not organ-specific and predominantly used for monitoring of colorectal cancer. Besides malignancies, also several benign diseases such as cirrhosis, bronchitis, pancreatitis and autoimmune diseases are associated with increased CEA serum levels. At 95% specificity towards benign lung diseases its sensitivity for lung cancer is reported to be 29-44%. A preferred use of CEA is therapy surveillance of lung cancer.
• NSE is a tumor marker for SCLC.
• increased NSE serum levels are found in association with neuroectodermal and neuroendocrine tumors. Increased serum levels are also found in patients with benign lung diseases and cerebral diseases, such as meningitis or other inflammatory diseases of the brain, and traumatic injuries to the head. While the sensitivity for SCLC at 95% specificity is reported to be 60-87%, the performance of NSE testing for NSCLC is poor (sensitivity of 7-25%). NSE is recommended for therapy surveillance of SCLC.
• ProGRP is a tumor marker, useful in the detection and monitoring of SCLC. Increased serum levels are also found in patients with nonmalignant lung/pleural diseases, such as idiopathic pulmonary fibrosis or sarcoidosis. While sensitivity for proGRP in the field of SCLC (at 95% specificity) is reported to be 47-86%, the performance of proGRP testing in the field of NSCLC is poor because the sensitivity is reported as being below 10%.
• SCC was originally identified in squamous cell CA of the cervix.
• the sensitivity of SCC for LC in general is low (18-27%). Therefore, SCC testing is regarded to be not suitable for screening.
• a preferred use for SCC is therapy surveillance, even though CYFRA 21-1 generally performs better.
• CYBP Calcyclin-binding protein, CacyBP, Siah-interacting protein, S100A6-binding protein
• hCYBP human CYBP
• the present invention relates to a method for assessing lung cancer in vitro comprising measuring in a sample the presence and/or concentration of CYBP, and using the measurement result, particularly the concentration determined in the assessment of lung cancer.
• novel marker CYBP may be used for monitoring as well as for screening purposes.
• the diagnostic method according to the present invention may help to assess tumor load, efficacy of treatment and tumor recurrence in the follow-up of patients.
• Increased levels of CYBP are directly correlated to tumor burden. After chemotherapy a short term (few hours to 14 days) increase in CYBP may serve as an indicator of tumor cell death. In the follow-up of patients (from 3 months to 10 years) an increase of CYBP can be used as an indicator for tumor recurrence.
• the diagnostic method according to the present invention is used for screening purposes. I.e., it is used to assess subjects without a prior diagnosis of LC by measuring the level of CYBP and correlating the level measured to the presence or absence of LC.
• the present invention is also directed to a method for assessing LC in vitro by biochemical markers, comprising measuring in a sample the presence and/or concentration of CYBP and of one or more other marker of LC and using the measurement results, particularly concentrations determined in the assessment of LC. It is preferred that the one or more other marker of LC is selected from the group consisting of CYFRA 21-1, CEA, NSE, proGRP and SCC.
• the present invention also relates to the use of a marker panel comprising CYBP and one or more additional marker in the assessment of LC, wherein a preferred additional marker is selected from the group consisting of CYFRA 21-1, CEA, NSE, proGRP and SCC.
• the present invention in a preferred embodiment, also relates to the use of a marker panel comprising at least CYBP and CYFRA 21-1 in the assessment of LC.
• the present invention also relates to the use of a marker panel comprising at least CYBP and CEA in the assessment of LC.
• the present invention also relates to the use of a marker panel comprising at least CYBP and SCC in the assessment of LC.
• the present invention further relates to a kit for performing the method according to the present invention comprising at least the reagents required to specifically measure CYBP and optionally auxiliary reagents for performing the measurement.
• the present invention also provides a kit for performing the method according to the present invention comprising at least the reagents required to specifically measure CYBP and CYFRA 21-1, respectively, and optionally auxiliary reagents for performing the measurement.
• the present invention also provides a kit for performing the methods according to the present invention comprising at least the reagents required to specifically measure CYBP and one or more other marker for lung cancer.
• the present invention also provides a kit for performing the method according to the present invention comprising at least the reagents required to specifically measure CYBP and CEA, respectively, and optionally auxiliary reagents for performing the measurement.
• the present invention also provides a kit for performing the method according to the present invention comprising at least the reagents required to specifically measure CYBP and SCC, respectively, and optionally auxiliary reagents for performing the measurement.
• the present invention relates to a method for assessing lung cancer in vitro comprising measuring in a sample the presence and/or concentration of a) CYBP, and b) optionally one or more other marker of lung cancer, and c) using the measurement results, particularly the concentrations determined in step (a) and optionally step (b) in the assessment of lung cancer.
• the term “measurement” comprises a qualitative or a quantitative measurement of CYBP in a sample.
• the measurement is a qualitative or semi-quantitative measurement, i.e., it is determined whether CYBP is present or absent or it is determined whether the concentration of CYBP is above or below a cut-off value.
• the assay sensitivity is usually set to match the cut-off value.
• a cut-off value can for example be determined from the testing of a group of healthy individuals.
• the cut-off is set to result in a specificity of 90%, also preferred the cut-off is set to result in a specificity of 95%, or also preferred the cut-off is set to result in a specificity of 98%. Presence of a value above the cut-off value can for example be indicative for the presence of lung cancer.
• the measurement is a quantitative measurement.
• the concentration of CYBP is correlated to an underlying diagnostic question like, e.g., stage of disease, disease progression, or response to therapy.
• Calcyclin is a calcium-binding protein that belongs to the family of S100 proteins (reviewed in Zimmer et al., Brain Res. Bull. 37 (1995), 417-429; Schumann and Cox, Biometals 11 (1998), 383-397). Its gene was discovered on the basis of its cell cycle-dependent expression (Calabretta et al., J. Biol. Chem. 261 (1986), 12628-12632). This gene is expressed at its maximal level during the transition between GO to S phase of the cell cycle, but its expression is deregulated in acute myeloid leukemia (Calabretta et al., Proc. Natl. Sci USA 83 (1986), 1495-1498).
• the protein was first purified and characterized from Ehrlich ascites tumor (EAT) cells (Kuznicki and Filipek, Biochem. J. 247 (1987), 663-667; Kuznicki et al., Biochem. J. 263 (1989), 951-956). Later calcyclin was found to be expressed at high levels in fibroblasts and epithelial cells, in cells with high proliferating activity, and those undergoing differentiation (Leonard et al., Mol. Cell. Biol. 7 (1987), 3156-3167; Guo et al., Cell Growth Differ. 1 (1990), 333-338; Tonini et al., Cancer Res. Si (1991), 1733-1737, Kuznicki et al., Exp. Cell. Res. 200 (1992), 425-430).
• EAT Ehrlich ascites tumor
• Calcyclin has been shown to interact in vitro in a Ca2+-dependent manner with glyceraldehyde-3-phosphate dehydrogenase, annexin II (Filipek et al., Eur. J. Biochem. 195 (1991), 795-800), annexin VI (Zeng et al., Int. J. Biochem. 25 (1993), 1019-1027), annexin XI (Tokumitsu et al., Biochem. Biophys. Res. Comm.
• CacyBP was initially identified, purified, and characterized from EAT cells (Filipek and Wojda (1996), supra). Amino acid sequencing of chymotryptic fragments suggested that it was a novel protein, so CacyBP was cloned from a mouse brain cDNA library and sequenced (Filipek and Kuznicki (1998), supra). The amino acid sequence of human CYBP (Swiss PROT Q9HB71) is depicted as SEQ ID NO: 1. Except for a recently submitted hypothetical protein, which is apparently a human homologue of CacyBP, the nucleotide sequence of CacyBP reveals no homology to any other sequence deposited in standard data bases.
• CacyBP Recombinant CacyBP was expressed in Escherichia coli , and its interaction with calcyclin was shown to occur at physiological calcium concentration (Filipek and Kuznicki (1998), supra). Recent studies revealed that CacyBP is present at high level in the mouse and rat brain, particularly in the neuronal cells (Jastrzebska et al., J. Histochem. Cytochem. 48 (2000), 1195-1202).
• CYBP may be involved in calcium-dependent ubiquitination and subsequent proteosomal degradation of target proteins. It probably serves as a molecular bridge in ubiquitin E3 complexes. It participates in the ubiquitin-mediated degradation of beta-catenin (CTNNB1).
• CYBP interacts with proteins of the 5100 family S100A1, S100A6, S100B, S100P and S100A12 at physiological calcium concentrations. It is a component of some large E3 complex at least composed of UBE2D1, SIAH1, CACYBP/SIP, SKP1, APC and TBL1X. It interacts directly with SIAH1, SIAH2 and SKP1.
• CYBP is localized in the nucleus and in cytoplasm at low calcium concentrations.
• RA retinoic acid
• the nuclear fraction may be phosphorylated.
• CYBP can be measured with high sensitivity in body fluids such as blood, serum or plasma.
• body fluids such as blood, serum or plasma.
• the inventors found out that a reliable assessment of LC is possible by measuring CYBP within a liquid sample from an individual, i.e., no tissue and no biopsy sample is required in diagnosis of LC when using protein CYBP as marker. Even more surprisingly it was found that an increased level of CYBP as measured from bodily fluid of an individual is associated with lung cancer.
• the present invention shall not be construed to be limited to the full-length protein CYBP of SEQ ID NO: 1.
• Physiological or artificial fragments of CYBP, secondary modifications of CYBP, as well as allelic variants of CYBP are also encompassed by the present invention.
• Artificial fragments preferably encompass a peptide produced synthetically or by recombinant techniques, which at least comprises one epitope of diagnostic interest consisting of at least 6 contiguous amino acids as derived from the sequence disclosed in SEQ ID NO: 1. Such fragment may advantageously be used for generation of antibodies or as a standard in an immunoassay. More preferred the artificial fragment comprises at least two epitopes of interest appropriate for setting up a sandwich immunoassay.
• a marker means one marker or more than one marker.
• the term “at least” is used to indicate that optionally one or more further objects may be present.
• a marker panel comprising at least (the markers) CYBP and CYFRA 21-1 may optionally comprise one or more other marker.
• one or more denotes 1 to 50, preferably 1 to 20 also preferred 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, or 15.
• marker refers to a molecule to be used as a target for analyzing a patient's test sample.
• examples of such molecular targets are proteins or polypeptides.
• Proteins or polypeptides used as a marker in the present invention are contemplated to include naturally occurring variants of said protein as well as fragments of said protein or said variant, in particular, immunologically detectable fragments.
• Immunologically detectable fragments preferably comprise at least 6, 7, 8, 10, 12, 15 or 20 contiguous amino acids of said marker polypeptide.
• proteins which are released by cells or present in the extracellular matrix may be damaged, e.g., during inflammation, and could become degraded or cleaved into such fragments.
• Certain markers are synthesized in an inactive form, which may be subsequently activated by proteolysis.
• proteins or fragments thereof may also be present as part of a complex.
• Such complex also may be used as a marker in the sense of the present invention.
• Variants of a marker polypeptide are encoded by the same gene, but may differ in their isoelectric point (PI) or molecular weight (MW), or both, e.g., as a result of alternative mRNA or pre-mRNA processing.
• the amino acid sequence of a variant is to 95% or more identical to the corresponding marker sequence.
• a marker polypeptide or a variant thereof may carry a post-translational modification.
• Preferred posttranslational modifications are glycosylation, acylation, and/or phosphorylation.
• the marker CYBP is specifically measured from a sample by use of a specific binding agent.
• a specific binding agent is, e.g., a receptor for CYBP, a lectin binding to CYBP or an antibody to CYBP.
• a specific binding agent has at least an affinity of 10 7 l/mol for its corresponding target molecule.
• the specific binding agent preferably has an affinity of 10 8 l/mol or also preferred of 10 9 l/mol for its target molecule.
• specific is used to indicate that other biomolecules present in the sample do not significantly bind to the binding agent specific for CYBP.
• the level of binding to a biomolecule other than the target molecule results in a binding affinity which is at most only 10% or less, only 5% or less only 2% or less or only 1% or less of the affinity to the target molecule, respectively.
• a preferred specific binding agent will fulfill both the above minimum criteria for affinity as well as for specificity.
• a specific binding agent preferably is an antibody reactive with CYBP.
• the term antibody refers to a polyclonal antibody, a monoclonal antibody, antigen binding fragments of such antibodies, single chain antibodies as well as to genetic constructs comprising the binding domain of an antibody.
• Antibodies are generated by state of the art procedures, e.g., as described in Tijssen (Tijssen, P., Practice and theory of enzyme immunoassays, 11, Elsevier Science Publishers B.V., Amsterdam, the whole book, especially pages 43-78).
• Tijssen Tejssen, P., Practice and theory of enzyme immunoassays, 11, Elsevier Science Publishers B.V., Amsterdam, the whole book, especially pages 43-78.
• the skilled artisan is well aware of methods based on immunosorbents that can be used for the specific isolation of antibodies. By these means the quality of polyclonal antibodies and hence their performance in immunoassays can be enhanced. (Tijssen, P., supra, pages 108-115).
• polyclonal antibodies raised in rabbits may be used.
• polyclonal antibodies from different species e.g., rats or guinea pigs
• monoclonal antibodies can be used. Since monoclonal antibodies can be produced in any amount required with constant properties, they represent ideal tools in development of an assay for clinical routine.
• CYBP has been identified as a marker which is useful in the assessment of lung cancer
• various immunodiagnostic procedures may be used to reach a result comparable to the achievements of the present invention.
• alternative strategies to generate antibodies may be used.
• Such strategies comprise amongst others the use of synthetic peptides, representing an epitope of CYBP for immunization.
• DNA immunization also known as DNA vaccination may be used.
• CYBP is detected in a sandwich type assay format.
• a first specific binding agent is used to capture CYBP on the one side and a second specific binding agent, which is labeled to be directly or indirectly detectable, is used on the other side.
• measurement of CYBP in a sample is carried out by using a sandwich immunoassay, wherein Streptavidin-coated microtiter plates are used.
• a biotinylated polyclonal antibody to CYBP is used as a capturing antibody and a digoxigenylated polyclonal antibody to CYBP is used as the second specific binding partner in this sandwich assay.
• the sandwich complex formed is finally visualized by an anti-digoxigenin horseradish peroxidase conjugate and an appropriate peroxidase substrate.
• a “marker of lung cancer” in the sense of the present invention is any marker that, if combined with the marker CYBP, adds relevant information in the assessment of LC.
• the information is considered relevant or of additive value if at a given specificity the sensitivity, or if at a given sensitivity the specificity, respectively, for the assessment of LC can be improved by including said marker into a marker combination already comprising the marker CYBP.
• the one or more other marker of LC is selected from the group consisting of CYFRA 21-1, CEA, NSE, proGRP and SCC.
• sample refers to a biological sample obtained for the purpose of evaluation in vitro.
• the sample or patient sample preferably may comprise any body fluid or a tissue extract.
• Preferred test samples include blood, serum, plasma, sputum and bronchial lavage.
• Preferred samples are whole blood, serum, plasma, bronchial lavage or sputum, with plasma being most preferred.
• assessing lung cancer is used to indicate that the method according to the present invention will (alone or together with other markers or variables, e.g., the criteria set forth by the UICC (see above)), e.g., aid the physician to establish or confirm the absence or presence of LC or aid the physician in the prognosis, the detection of recurrence (follow-up of patients after surgery), screening and/or the monitoring of treatment, especially of chemotherapy.
• markers or variables e.g., the criteria set forth by the UICC (see above)
• any such assessment is made in vitro.
• the patient sample is discarded afterwards.
• the patient sample is solely used for the in vitro diagnostic method of the invention and the material of the patient sample is not transferred back into the patient's body.
• the sample is a liquid sample, e.g., whole blood, serum, or plasma.
• the inventors of the present invention have surprisingly been able to detect the marker protein CYBP in a significant percentage of samples derived from patients with LC. Even more surprising they have been able to demonstrate that the presence and/or concentration of CYBP in such sample obtained from an individual can be used in the assessment of lung cancer.
• the ideal scenario for diagnosis would be a situation wherein a single event or process would cause the respective disease as, e.g., in infectious diseases. In all other cases correct diagnosis can be very difficult, especially when the etiology of the disease is not fully understood as is the case for LC.
• no biochemical marker is diagnostic with 100% specificity and at the same time 100% sensitivity for a given multifactorial disease, for example for LC.
• biochemical markers e.g., CYFRA 21-1, CEA, NSE, proGRP, SCC, or as shown here CYBP can be used to assess with a certain likelihood or predictive value, e.g., the presence, absence, or the severity of a disease. Therefore in routine clinical diagnosis, generally various clinical symptoms and biological markers are considered together in the diagnosis, treatment and management of the underlying disease.
• Biochemical markers can either be determined individually or in a preferred embodiment of the invention they can be measured simultaneously using a chip or a bead based array technology. The concentrations of the biomarkers are then either interpreted independently, e.g., using an individual cut-off for each marker, or they are combined for interpretation.
• the assessment of LC according to the present invention is performed in a method comprising measuring in a sample the presence and/or concentration of a) CYBP, and b) one or more other marker of lung cancer, and c) using the measurement result, e.g., the concentrations determined in step (a) and step (b), respectively, in the assessment of lung cancer.
• the marker CYBP will be of advantage in one or more of the following aspects: screening; diagnostic aid; prognosis; monitoring of therapy such as chemotherapy, radiotherapy, and immunotherapy.
• Screening is defined as the systematic application of a test to identify individuals, e.g., at risk individuals, for indicators of a disease, e.g., the presence of lung cancer.
• the screening population is composed of individuals known to be at higher than average risk of lung cancer, like smokers, ex-smokers, and uranium-, quartz- or asbestos-exposed workers.
• sputum is used as a sample in the screening for lung cancer.
• a marker panel comprising a plurality of markers will have to be used in LC screening.
• the data established in the present invention indicate that the marker CYBP will form an integral part of a marker panel appropriate for screening purposes.
• the present invention therefore relates to the use of CYBP as one marker of a LC marker panel, i.e., a marker panel comprising CYBP and one or more additional marker for LC screening purposes.
• Preferred additional markers are selected from the group consisting of CYFRA 21-1, CEA, NSE, proGRP and SCC.
• Markers may either aid the differential diagnosis of benign vs. malignant disease in a particular organ, help to distinguish between different histological types of a tumor, or to establish baseline marker values before surgery.
• CT computed tomography
• the marker CYBP is used in an immunohistological method in order to establish or confirm different histological types of LC.
• CYBP as a single marker might be superior to other LC markers like CEA or NSE it has to be expected that CYBP will be used as a diagnostic aid, especially by establishing a baseline value before surgery.
• the present invention thus also relates to the use of CYBP for establishing a baseline value before surgery for LC.
• Prognostic indicators can be defined as clinical, pathological, or biochemical features of cancer patients and their tumors that predict with a certain likelihood the disease outcome. Their main use is to help to rationally plan patient management, i.e., to avoid undertreatment of aggressive disease and overtreatment of indolent disease, respectively.
• Molina R. et al., Tumor Biol. (2003) 24:209-218 evaluated the prognostic value of CEA, CA 125, CYFRA 21-1, SSC and NSE in NSCLC. In their study abnormal serum levels of the markers NSE, CEA, and LDH (lactate dehydrogenase) appeared to indicate shorter survival.
• CYBP is used in the prognosis of patients with LC.
• CEA studies suggested: a) that patients with a decrease in CEA levels while receiving chemotherapy generally had a better outcome than those patients whose CEA levels failed to decrease and (b) for almost all patients, increases in CEA levels were associated with disease progression.
• CYBP will be at least as good a marker for monitoring of chemotherapy as CYFRA 21-1 or CEA, respectively.
• the present invention therefore also relates to the use of CYBP in the monitoring of LC patients under chemotherapy.
• CYBP CYBP alone or in combination with one or more other marker will be of great help in the follow-up of LC patients, especially in LC patients after surgery.
• the use of a marker panel comprising CYBP and one or more other marker of LC in the follow-up of LC patients represents a further preferred embodiment of the present invention.
• the present invention in a preferred embodiment relates to the use of CYBP in the diagnostic field of LC or in the assessment of LC, respectively.
• the present invention relates to the use of CYBP as a marker molecule for lung cancer in combination with one or more marker molecules for lung cancer in the assessment of lung cancer from a liquid sample obtained from an individual.
• Preferred selected other LC markers with which the measurement of CYBP may be combined are CYFRA 21-1, CEA, NSE, proGRP, and/or SCC.
• the marker panel used in the assessment of LC comprises CYBP and at least one other marker molecule selected from the group consisting of CYFRA 21-1 and CEA.
• markers of a marker panel e.g., for CYBP and CYFRA 21-1
• values measured for markers of a marker panel are mathematically combined and the combined value is correlated to the underlying diagnostic question.
• Marker values may be combined by any appropriate state of the art mathematical method.
• DA discriminant analysis
• SVM Kernel Methods
• Nonparametric Methods i.e., k-Nearest-Neighbor Classifiers
• PLS Partial Least Squares
• Tree-Based Methods i.e., Logic Regression, CART, Random Forest Methods, Boosting/Bagging Methods
• Generalized Linear Models i.e., Logistic Regression
• Principal Components based Methods i.e., SIMCA
• Additive Models Fuzzy Logic based Methods, Neural Networks and Genetic Algorithms based Methods.
• the method used in correlating the marker combination of the invention, e.g., to the absence or presence of LC is selected from DA (i.e., Linear-, Quadratic-, Regularized Discriminant Analysis), Kernel Methods (i.e., SVM), Nonparametric Methods (i.e., k-Nearest-Neighbor Classifiers), PLS (Partial Least Squares), Tree-Based Methods (i.e., Logic Regression, CART, Random Forest Methods, Boosting Methods), or Generalized Linear Models (i.e., Logistic Regression).
• DA i.e., Linear-, Quadratic-, Regularized Discriminant Analysis
• Kernel Methods i.e., SVM
• Nonparametric Methods i.e., k-Nearest-Neighbor Classifiers
• PLS Partial Least Squares
• Tree-Based Methods i.e., Logic Regression, CART, Random Forest Methods
• state A e.g., diseased from healthy.
• state B e.g., diseased from healthy.
• the markers are no longer independent but form a marker panel.
• ROC receiver-operating characteristics
• the clinical performance of a laboratory test depends on its diagnostic accuracy, or the ability to correctly classify subjects into clinically relevant subgroups. Diagnostic accuracy measures the test's ability to correctly distinguish two different conditions of the subjects investigated. Such conditions are for example health and disease or benign versus malignant disease.
• the ROC plot depicts the overlap between the two distributions by plotting the sensitivity versus 1—specificity for the complete range of decision thresholds.
• sensitivity or the true-positive fraction [defined as (number of true-positive test results)/(number of true-positive+number of false-negative test results)]. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup.
• false-positive fraction or 1 ⁇ specificity [defined as (number of false-positive results)/(number of true-negative+number of false-positive results)]. It is an index of specificity and is calculated entirely from the unaffected subgroup.
• the ROC plot is independent of the prevalence of disease in the sample.
• Each point on the ROC plot represents a sensitivity/1-specificity pair corresponding to a particular decision threshold.
• a test with perfect discrimination has an ROC plot that passes through the upper left corner, where the true-positive fraction is 1.0, or 100% (perfect sensitivity), and the false-positive fraction is 0 (perfect specificity).
• the theoretical plot for a test with no discrimination is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall in between these two extremes.
• One preferred way to quantify the diagnostic accuracy of a laboratory test is to express its performance by a single number.
• the present invention relates to a method for improving the diagnostic accuracy for LC versus healthy controls by measuring in a sample the concentration of at least CYBP and CYFRA 21-1, and optionally of CEA, proGRP, NSE, and/or SCC, respectively and correlating the concentrations determined to the presence or absence of LC, the improvement resulting in more patients being correctly classified as suffering from LC versus healthy controls as compared to a classification based on any single marker investigated alone.
• At least the concentration of the biomarkers CYBP and CEA, respectively, is determined and the marker combination is used in the assessment of LC.
• At least the concentration of the biomarkers CYBP, CYFRA 21-1, and CEA, respectively, is determined and the marker combination is used in the assessment of LC.
• At least the concentration of the biomarkers CYBP, CYFRA 21-1, and SCC, respectively, is determined and the marker combination is used in the assessment of LC.
• a polyclonal antibody preparations to the lung cancer marker protein CYBP is generated for further use of the antibody in the measurement of serum and plasma and blood levels of CYBP by immunodetection assays, e.g., Western Blotting and ELISA.
• the CYBP coding region is PCR amplified from a full-length CYBP-cDNA clone coding for the 227 amino acids as specified in SEQ ID NO: 1 using suitable forward and reverse primers.
• the forward primer features (besides the EcoRI cloning and ribosomal binding sites) oligonucleotides coding for an N-terminal MRGSHHHHHHIEGR peptide extension (SEQ ID NO: 2) introduced in-frame to the CYBP polypeptide.
• the EcoRI/BamHI digested PCR fragment is ligated into the corresponding pQE-30 (Qiagen, Hilden, Germany) vector fragment which is subsequently transformed into E. coli XL1-blue competent cells. After sequence analysis, the plasmid is transformed into E. coli BL21 competent cells for expression under the IPTG-inducible T5 promoter of the pQE vector series following the manufacturer's instructions.
• Ni-NTA Ni-nitrilotriacetic acid
• bound antigen is eluted with an imidazol gradient from 20 to 500 mM in 20 mM sodium-phosphate buffer, 500 mM sodium chloride, pH 7.4 and stored in 75 mM HEPES-buffer, pH 7.5, 100 mM sodium chloride, 1 mM EDTA, 6.5% sucrose at 4° C.
• a fresh emulsion of the protein solution (100 ⁇ g/ml protein CYBP) and complete Freund's adjuvant at the ratio of 1:1 is prepared.
• Each rabbit is immunized with 1 ml of the emulsion at days 1, 7, 14 and 30, 60 and 90. Blood is drawn and resulting anti-CYBP serum is used as described hereinbelow.
• rabbit serum is diluted with 4 volumes of acetate buffer (60 mM, pH 4.0). The pH is adjusted to 4.5 with 2 M Tris-base. Caprylic acid (25 ⁇ l/ml of diluted sample) is added drop-wise under vigorous stirring. After 30 min the sample is centrifuged (13 000 ⁇ g, 30 min, 4° C.), the pellet discarded and the supernatant collected. The pH of the supernatant is adjusted to 7.5 by the addition of 2 M Tris-base.
• the immunoglobulin in the supernatant is precipitated under vigorous stirring by the drop-wise addition of a 4 M ammonium sulfate solution to a final concentration of 2 M.
• the precipitated immunoglobulins are collected by centrifugation (8000 ⁇ g, 15 min, 4° C.).
• the supernatant is discarded.
• the pellet is dissolved in 10 mM NaH 2 PO 4 /NaOH, pH 7.5, 30 mM NaCl and exhaustively dialyzed.
• the dialysate is centrifuged (13 000 ⁇ g, 15 min, 4° C.) and filtered (0.2 ⁇ m).
• Polyclonal rabbit IgG is brought to 10 mg/ml in 10 mM NaH 2 PO 4 /NaOH, pH 7.5, 30 mM NaCl. Per ml IgG solution 50 ⁇ l Biotin-N-hydroxysuccinimide (3.6 mg/ml in DMSO) are added. After 30 min at room temperature, the sample is chromatographed on Superdex 200 (10 mM NaH 2 PO 4 /NaOH, pH 7.5, 30 mM NaCl). The fractions containing biotinylated IgG are collected.
• Polyclonal rabbit IgG is brought to 10 mg/ml in 10 mM NaH 2 PO 4 /NaOH, 30 mM NaCl, pH 7.5.
• Per ml IgG solution 50 ⁇ l digoxigenin-3-O-methylcarbonyl-E-aminocaproic acid-N-hydroxysuccinimide ester (Roche Diagnostics, Mannheim, Germany, Cat. No. 1 333 054) (3.8 mg/ml in DMSO) are added. After 30 min at room temperature, the sample is chromatographed on Superdex® 200 (10 mM NaH 2 PO 4 /NaOH, pH 7.5, 30 mM NaCl). The fractions containing digoxigenylated IgG are collected.
• a sandwich ELISA is developed.
• anti-CYBP polyclonal antibody (see Example 1) is conjugated with biotin and immobilized on a streptavidin-coated surface and for detection of the antigen anti-CYBP polyclonal antibody is conjugated with digoxigenin.
• Streptavidin-coated microtiter plates are incubated with 100 ⁇ l biotinylated anti-CYBP polyclonal antibody (1 ⁇ g/ml) per well for 10 min at room temperature. Subsequently plates are washed three times with PBS, 0.05% Tween 20. Wells are then incubated for 2 h with either a serial dilution of the recombinant protein (see Example 1) as standard antigen or with diluted EDTA-plasma samples from patients together with 5 ⁇ g/ml digoxigenin-conjugated anti-CYBP polyclonal antibody. Incubation was in an incubation buffer (PBS comprising 0.1% Tween 20, 1% BSA).
• the levels of CYBP, CEA and CYFRA21-1 in the LC samples are evaluated.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Hospice & Palliative Care (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Oncology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Ultra Sonic Daignosis Equipment (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (4)

Related Parent Applications (1)

Publications (2)

Family

ID=40902073

Family Applications (1)

Country Status (8)

Families Citing this family (4)

Citations (6)

• 2010
  • 2010-05-17 CN CN201080018804.4A patent/CN102439455B/zh not_active Expired - Fee Related
  • 2010-05-17 ES ES10722044.4T patent/ES2493069T3/es active Active
  • 2010-05-17 EP EP10722044.4A patent/EP2430450B1/en not_active Not-in-force
  • 2010-05-17 WO PCT/EP2010/056730 patent/WO2010130839A1/en active Application Filing
  • 2010-05-17 CA CA2761873A patent/CA2761873A1/en not_active Abandoned
  • 2010-05-17 JP JP2012510316A patent/JP5571171B2/ja not_active Expired - Fee Related
• 2011
  • 2011-10-11 US US13/270,482 patent/US8951738B2/en not_active Expired - Fee Related
• 2012
  • 2012-06-13 HK HK12105762.1A patent/HK1165204A1/xx not_active IP Right Cessation

Patent Citations (7)

Non-Patent Citations (40)

Also Published As

Similar Documents

Legal Events